#experimental therapies

The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.

None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.

Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.

Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.

Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.

Results from randomized clinical trials of the antiviral drug continue to show mixed results.

Cancer-fighting T cells led to complete or partial tumor remission in at least 25% of lung cancer patients.

Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.

The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.

Our spring issue is devoted to the theme of treatment.

MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.

Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.

Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.

New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.